Recently, Zafarana et al. (48) reported for the first time the combined role of PTEN loss and MYC gain using global high-resolution CGH analyses validated by FISH in a cohort of 126 intermediate-risk prostate cancer patients after receiving radiotherapy. This evidence concerns the gene PTEN and prostate carcinoma.